Aragon in the News

• August 9, 2010

  Aragon Pharmaceuticals Doses First Patient in Phase 1/2 Clinical Trial of ARN-509 for Castration-Resistant Prostate Cancer

• August 2, 2010

  Aragon Pharmaceuticals Appoints Richard A. Heyman CEO

• April 22, 2010

  Aragon Pharmaceuticals Secures $22 Million in Series B Financing

• October 27, 2009

  Aragon Pharmaceuticals' Founder, Dr. Charles Sawyers Awarded 2009 Lasker-DeBakey Clinical Medical Research Award

• May 20, 2009

  Aragon Pharmaceuticals Announces $8 Million Series A Financing